Acadian Asset Management’s CytomX Therapeutics CTMX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-63,694
| Closed | -$298K | – | 2038 |
|
|
2026
Q1 | $298K | Sell |
63,694
-792,362
| -93% | -$4.02M | ﹤0.01% | 1485 |
|
|
2025
Q4 | $3.64M | Buy |
856,056
+202,331
| +31% | +$769K | 0.01% | 734 |
|
|
2025
Q3 | $2.08M | Sell |
653,725
-903,311
| -58% | -$2.03M | ﹤0.01% | 881 |
|
|
2025
Q2 | $3.53M | Sell |
1,557,036
-1,676,999
| -52% | -$2.7M | 0.01% | 673 |
|
|
2025
Q1 | $2.05M | Buy |
3,234,035
+96,989
| +3% | +$75.2K | 0.01% | 748 |
|
|
2024
Q4 | $3.23M | Buy |
3,137,046
+36,052
| +1% | +$38.8K | 0.01% | 643 |
|
|
2024
Q3 | $3.65M | Buy |
3,100,994
+372,425
| +14% | +$473K | 0.01% | 576 |
|
|
2024
Q2 | $3.32M | Buy |
2,728,569
+37,739
| +1% | +$75.1K | 0.01% | 616 |
|
|
2024
Q1 | $5.86M | Buy |
2,690,830
+44,640
| +2% | +$82.4K | 0.02% | 434 |
|
|
2023
Q4 | $4.1M | Hold |
2,646,190
| – | – | 0.02% | 505 |
|
|
2023
Q3 | $3.41M | Sell |
2,646,190
-7,386
| -0.3% | -$11.6K | 0.01% | 547 |
|
|
2023
Q2 | $4.56M | Hold |
2,653,576
| – | – | 0.02% | 486 |
|
|
2023
Q1 | $4.01M | Hold |
2,653,576
| – | – | 0.02% | 517 |
|
|
2022
Q4 | $4.24M | Hold |
2,653,576
| – | – | 0.02% | 490 |
|
|
2022
Q3 | $3.85M | Buy |
2,653,576
+814,350
| +44% | +$1.25M | 0.02% | 476 |
|
|
2022
Q2 | $3.37M | Buy |
1,839,226
+954,119
| +108% | +$1.83M | 0.02% | 510 |
|
|
2022
Q1 | $2.36M | Buy |
885,107
+473,885
| +115% | +$1.82M | 0.01% | 631 |
|
|
2021
Q4 | $1.78M | Sell |
411,222
-289,768
| -41% | -$1.7M | 0.01% | 687 |
|
|
2021
Q3 | $3.56M | Sell |
700,990
-348,149
| -33% | -$1.86M | 0.01% | 533 |
|
|
2021
Q2 | $6.64M | Buy |
1,049,139
+102,178
| +11% | +$796K | 0.03% | 396 |
|
|
2021
Q1 | $7.32M | Buy |
946,961
+259,071
| +38% | +$2.05M | 0.03% | 385 |
|
|
2020
Q4 | $4.51M | Buy |
687,890
+105,675
| +18% | +$755K | 0.02% | 524 |
|
|
2020
Q3 | $3.87M | Buy |
582,215
+286,216
| +97% | +$2.12M | 0.02% | 499 |
|
|
2020
Q2 | $2.46M | Buy |
295,999
+23,816
| +9% | +$221K | 0.01% | 680 |
|
|
2020
Q1 | $2.09M | Buy |
272,183
+68,641
| +34% | +$479K | 0.01% | 593 |
|
|
2019
Q4 | $1.69M | Buy |
203,542
+109,909
| +117% | +$742K | 0.01% | 737 |
|
|
2019
Q3 | $691K | Sell |
93,633
-56,209
| -38% | -$554K | ﹤0.01% | 999 |
|
|
2019
Q2 | $1.68M | Buy |
149,842
+29,568
| +25% | +$310K | 0.01% | 667 |
|
|
2019
Q1 | $1.29M | Buy |
+120,274
| New | +$1.78M | 0.01% | 814 |
|
|
2018
Q3 | – | Sell |
-50,883
| Closed | -$1.16M | – | 1678 |
|
|
2018
Q2 | $1.16M | Sell |
50,883
-22,406
| -31% | -$572K | 0.01% | 694 |
|
|
2018
Q1 | $2.09M | Buy |
+73,289
| New | +$2.09M | 0.01% | 580 |
|
|
2017
Q4 | – | Sell |
-1,608
| Closed | -$29K | – | 1593 |
|
|
2017
Q3 | $29K | Sell |
1,608
-2,524
| -61% | -$39.4K | ﹤0.01% | 1171 |
|
|
2017
Q2 | $64K | Buy |
+4,132
| New | +$62.3K | ﹤0.01% | 1096 |
|
Other funds holding CTMX
KCM
PA
VA
Acadian Asset Management's CTMX Position: Q2 2026 in Review
Acadian Asset Management sold out of CytomX Therapeutics (CTMX) in Q2 2026, closing a stake of 63,694 shares — an estimated $298K sold.
Acadian Asset Management first reported a position in CTMX in Q2 2017 and held it in 33 quarters. The position peaked at $7.32M in Q1 2021. 178 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.
- Acadian Asset Management reported no remaining CytomX Therapeutics position as of Q2 2026 after selling out during the quarter.
- Acadian Asset Management sold 63,694 CytomX Therapeutics shares in Q2 2026, an estimated $298K.
- Acadian Asset Management first reported a position in CytomX Therapeutics in Q2 2017 and held it in 33 quarters.
- Acadian Asset Management's CytomX Therapeutics position peaked at $7.32M in Q1 2021.
- 178 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.
Based on Acadian Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.